1. Home
  2. JVSA vs CNTB Comparison

JVSA vs CNTB Comparison

Compare JVSA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JVSA
  • CNTB
  • Stock Information
  • Founded
  • JVSA 2021
  • CNTB 2012
  • Country
  • JVSA Hong Kong
  • CNTB United States
  • Employees
  • JVSA N/A
  • CNTB N/A
  • Industry
  • JVSA
  • CNTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • JVSA
  • CNTB Health Care
  • Exchange
  • JVSA NYSE
  • CNTB Nasdaq
  • Market Cap
  • JVSA 79.7M
  • CNTB 65.5M
  • IPO Year
  • JVSA 2024
  • CNTB 2021
  • Fundamental
  • Price
  • JVSA $10.38
  • CNTB $0.99
  • Analyst Decision
  • JVSA
  • CNTB Strong Buy
  • Analyst Count
  • JVSA 0
  • CNTB 1
  • Target Price
  • JVSA N/A
  • CNTB $8.00
  • AVG Volume (30 Days)
  • JVSA 1.2K
  • CNTB 27.1K
  • Earning Date
  • JVSA 01-01-0001
  • CNTB 09-05-2024
  • Dividend Yield
  • JVSA N/A
  • CNTB N/A
  • EPS Growth
  • JVSA N/A
  • CNTB N/A
  • EPS
  • JVSA N/A
  • CNTB N/A
  • Revenue
  • JVSA N/A
  • CNTB $24,116,000.00
  • Revenue This Year
  • JVSA N/A
  • CNTB N/A
  • Revenue Next Year
  • JVSA N/A
  • CNTB $63.90
  • P/E Ratio
  • JVSA $58.13
  • CNTB N/A
  • Revenue Growth
  • JVSA N/A
  • CNTB N/A
  • 52 Week Low
  • JVSA $10.02
  • CNTB $0.68
  • 52 Week High
  • JVSA $10.42
  • CNTB $2.84
  • Technical
  • Relative Strength Index (RSI)
  • JVSA N/A
  • CNTB 33.74
  • Support Level
  • JVSA N/A
  • CNTB $1.00
  • Resistance Level
  • JVSA N/A
  • CNTB $1.09
  • Average True Range (ATR)
  • JVSA 0.00
  • CNTB 0.09
  • MACD
  • JVSA 0.00
  • CNTB -0.02
  • Stochastic Oscillator
  • JVSA 0.00
  • CNTB 4.85

About JVSA JVSPAC ACQUISITION CORP

JVSPAC Acquisition Corp is blank check company.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: